4.7 Article

Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies

期刊

EUROPEAN JOURNAL OF CANCER
卷 47, 期 1, 页码 74-83

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2010.09.007

关键词

Pregnancy after breast cancer; Safety; Counselling; Fertility; Healthy mother effect

类别

向作者/读者索取更多资源

Background: Due to the rising trend of delaying pregnancy to later in life, more women are diagnosed with breast cancer before completing their families. Therefore, enquiry into the feasibility and safety of pregnancy following breast cancer diagnosis is on the rise. Available evidence suggests that women with a history of breast cancer are frequently advised against future conception for fear that pregnancy could adversely affect their breast cancer outcome. Hence, we conducted a meta-analysis to understand the effect of pregnancy on overall survival of women with a history of breast cancer. Methods: Two of the authors independently performed a literature search up to September 2009 with no language restrictions. Eligible studies were published retrospective control-matched, population-based and hospital-based studies that have addressed the impact of pregnancy on the overall survival of women with history of breast cancer. Pooling of data was done using the random effect model. Unpublished statistics from three studies were obtained to perform further subgroup and sensitivity analyses. This included examining the effect of pregnancy according to age at diagnosis, healthy mother effect, type of study, nodal status and other parameters. Results: Fourteen studies were included in this meta-analysis (1244 cases and 18,145 controls). Women who got pregnant following breast cancer diagnosis had a 41% reduced risk of death compared to women who did not get pregnant [PRR: 0.59 (90% confidence interval (CI): 0.50-0.70)]. This difference was seen irrespective of the type of the study and particularly in women with history of node-negative disease. In a subgroup analysis, we compared the outcome of women with history of breast cancer who became pregnant to breast cancer patients who did not get pregnant and were known to be free of relapse. In this analysis, we did not find significant differences in survival between either group [PRR: 0.85; 95% CI: 0.53-1.35]. Conclusions: This study confirms that pregnancy in women with history of breast cancer is safe and does not compromise their overall survival. Hence, breast cancer survivors should not be denied the opportunity of future conception. (C) 2010 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

A multidisciplinary evaluation for advanced supportive care of breast cancer patients

Adelina Petrone, Marta Carlesimo, Maria Caterina Fortuna, Fedro Alessandro Peccatori, Giovanni Codacci-Pisanelli, Raffaele Barbara, Sara Cruciani, Pier Andrea Serra, Laura Maioli, Margherita Maioli, Gloria Trocchi

Summary: The prevalence of cancer is increasing due to rising incidence of tumors and more effective treatments. Many oncological treatments are associated with cutaneous toxicity, which may become chronic or permanent. Collaboration between specialists in different branches can help prevent and manage cutaneous toxicity in cancer patients.

BREAST CARE (2023)

Review Oncology

Immune plasticity in pregnancy-associated breast cancer tumorigenesis

Konstantinos Venetis, Elham Sajjadi, Fedro A. Peccatori, Elena Guerini-Rocco, Nicola Fusco

Summary: Pregnancy-associated breast cancer is a rare tumor that requires complex management. The coexistence of cancer and pregnancy involves shared proliferative, invasive, and immune tolerance mechanisms. The understanding of these mechanisms could lead to the identification of novel biomarkers and improved clinical management for patients with pregnancy-associated breast cancer.

EUROPEAN JOURNAL OF CANCER PREVENTION (2023)

Review Oncology

Lymphomas in pregnancy

Maria Cristina Pirosa, Fedro Alessandro Peccatori

Summary: Lymphoma in pregnancy is a rare condition that requires a multidisciplinary approach for management. The choice of treatment depends on the type of lymphoma and gestational age. ABVD is safe for Hodgkin lymphoma after the thirteenth week of pregnancy, while a watchful waiting approach is reasonable for indolent non-Hodgkin lymphomas. Termination of pregnancy may be considered for aggressive NHLs in early gestational weeks, while R-CHOP regimen is safe after the thirteenth week. More data on the safety of new anti-lymphoma drugs in pregnant patients is needed to facilitate clinical decision making.

HEMATOLOGICAL ONCOLOGY (2023)

Article Oncology

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*

David Cibula, Maria Rosaria Raspollini, Francois Planchamp, Carlos Centeno, Cyrus Chargari, Ana Felix, Daniela Fischerova, Daniela Jahnn-Kuch, Florence Joly, Christhardt Kohler, Sigurd Lax, Domenica Lorusso, Umesh Mahantshetty, Patrice Mathevet, Raj Naik, Remi A. Nout, Ana Oaknin, Fedro Peccatori, Jan Persson, Denis Querleu, Sandra Rubio Bernabe, Maximilian P. Schmid, Artem Stepanyan, Valentyn Svintsitskyi, Karl Tamussino, Ignacio Zapardiel, Jacob Lindegaard

Summary: In 2018, ESGO, ESTRO, and ESP jointly published evidence-based guidelines for the management of patients with cervical cancer. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Article Nursing

From Pregnancy to Lactation: When the Pathway is Complicated by Cancer

Martina Smorti, Lucia Ponti, Chiara Cassani, Giuseppe Nastasi, Nicola Giuntini, Gabriella Pravettoni, Fedro A. Peccatori, Giulia Mauri, Giovanni Danesi, Francesca Pozza, Valentina Sarchi, Lucia Bonassi

Summary: This study explored the differences in pregnancy and infant feeding experiences between pregnant women with a cancer history and those without. The results showed that women with a cancer history had a higher perception of negative judgment and moral choice about breastfeeding. However, they had a more positive childbirth experience and higher levels of satisfaction and pleasure in infant feeding.

JOURNAL OF HUMAN LACTATION (2023)

Editorial Material Geriatrics & Gerontology

Should cancer treatment stop at the age of 75?

Riccardo Audisio, Lodovico Balducci, Silvio Monfardini, Fedro A. Peccatori, Siri Rostoft, Barbara van Leeuwen

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

Article Medicine, General & Internal

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Saetersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frederic Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E. Lee, Janice M. Walshe, Manuel Ruiz-Borrego, Halle C. F. Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani

Summary: This study evaluated the risk of breast cancer recurrence among young breast cancer patients who temporarily discontinued hormone therapy to attempt pregnancy. The results showed that this interruption in therapy did not increase the risk of breast cancer events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Oncology

Healthcare Professional Communication on Sexual Health: A Report from the Italian Working Group on Adolescents and Young Adults with Cancer

Paola Quarello, Angela Toss, Paola Berchialla, Maurizio Mascarin, Matteo Lambertini, Marta Canesi, Giuseppe Maria Milano, Lorena Incorvaia, Giuseppe Luigi Banna, Fedro Peccatori, Andrea Ferrari

Summary: This study aims to explore the attitude of Italian healthcare professionals towards sexual health communication with AYA patients. The findings reveal that lack of preparation and embarrassment are barriers to communication, and less than 5% of clinicians received specific training on sexual health issues in AYA patients.

ONCOLOGIST (2023)

Editorial Material Oncology

The Oncohumanities training programme: Fostering a deeper engagement and integration of oncology and humanities to tackle the pressing and complex challenges of cancer care

Daniele Carrieri, Fedro Alessandro Peccatori, Giovanni Boniolo

Summary: 'Oncohumanities' is a new field that combines humanities and oncology to address the real needs and priorities of patients. A training program is proposed to integrate conceptual knowledge of oncology with person-centered care, patient empowerment, and respect for diversity. Oncohumanities differs from traditional medical humanities training as it is integrated with and driven by the needs of daily oncology practice. It is hoped that this program and approach will guide future efforts to strengthen the partnership between humanities and oncology.

TUMORI JOURNAL (2023)

Article Pathology

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*

David Cibula, Maria Rosaria Raspollini, Francois Planchamp, Carlos Centeno, Cyrus Chargari, Ana Felix, Daniela Fischerova, Daniela Jahnn-Kuch, Florence Joly, Christhardt Kohler, Sigurd Lax, Domenica Lorusso, Umesh Mahantshetty, Patrice Mathevet, Raj Naik, Remi A. Nout, Ana Oaknin, Fedro Peccatori, Jan Persson, Denis Querleu, Sandra Rubio Bernabe, Maximilian P. Schmid, Artem Stepanyan, Valentyn Svintsitskyi, Karl Tamussino, Ignacio Zapardiel, Jacob Lindegaard

Summary: In 2018, the European Society of Gynecological Oncology (ESGO) collaborated with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) to publish evidence-based guidelines for the management of cervical cancer. These updated guidelines cover all relevant issues of diagnosis and treatment, and were developed by a panel of 27 experts from across Europe.

VIRCHOWS ARCHIV (2023)

Review Oncology

Characterization of the immune environment in pregnancy-associated breast cancer

Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, Fedro Alessandro Peccatori, Nicola Fusco, Elena Guerini-Rocco

Summary: Pregnancy-associated breast cancer (PrBC) affects a small number of women and has unique immune characteristics. Understanding the immune environment of PrBC can provide insights for better clinical management, but current research on this topic is limited.

FUTURE ONCOLOGY (2023)

Article Oncology

Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database

Daniela Pierannunzio, Alice Maraschini, Tania Lopez, Serena Donati, Rosalba Amodio, Fortunato Bianconi, Rossella Bruni, Marine Castaing, Claudia Cirilli, Giovanna Fantaci, Linda Guarda, Silvia Iacovacci, Lucia Mangone, Guido Mazzoleni, Walter Mazzucco, Anna Melcarne, Elisabetta Merlo, Fabio Parazzini, Fedro Alessandro Peccatori, Massimo Rugge, Giuseppe Sampietro, Giovanni Scambia, Giovanna Scarfone, Ausilia Sferrazza, Fabrizio Stracci, Antonina Torrisi, Maria Francesca Vitale, Silvia Francisci

Summary: Concurrence of pregnancy and cancer diagnosis is becoming more common due to the trend of postponing childbearing. This study aims to describe the frequency and trend of pregnancy-associated cancer (PAC) in Italy. The study found that PAC has been increasing from 2003 to 2015, with breast cancer being the most frequent type. The findings provide guidance for clinicians in managing PAC.

CANCERS (2023)

Meeting Abstract Oncology

Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)

Ann Partridge, Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Saetersdal, Judith Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frederic Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice Walshe, Manuel Ruiz Borrego, Halle Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro Vilarino, Karin Ribi, Kathryn Ruddy, Sarra El-Abed, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber

CANCER RESEARCH (2023)

Meeting Abstract Oncology

The tumor immune microenvironment composition and prognostic value in breast cancer during pregnancy is dynamic during the gestation period

Elham Sajjadi, Konstantinos Venetis, Mariia Ivanova, Marianna Noale, Concetta Blundo, Giovanna Scarfone, Eugenia Di Loreto, Stefano Ferrero, Stefania Maggi, Paolo Veronesi, Viviana Enrica Galimbreti, Giuseppe Viale, Fedro Alessandro A. Peccatori, Elena Guerini-Rocco, Nicola Fusco

CANCER RESEARCH (2023)

Article Law

The regulatory impact of a harmonized artificial intelligence regulation proposal on the clinical research landscape in the European Union

Alma Linkeviciute, Giuseppe Curigliano, Fedro Alessandro Peccatori, Paulius Pakutinskas

Summary: This article critically analyzes how the proposed Artificial Intelligence Act (AIA) will support the rights, safety, dignity, and well-being of clinical research participants and ensure the availability of reliable and robust data. The focus is on the impact of the proposed regulation on clinical research within the European Union and how it aligns with the core principles of the Clinical Trials Regulation.

BIOLAW JOURNAL-RIVISTA DI BIODIRITTO (2022)

Article Oncology

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo

Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi

Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri

Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Impact of colorectal cancer screening on survival after metachronous metastasis

Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman

Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY)

Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia

Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study

Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond

Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.

EUROPEAN JOURNAL OF CANCER (2024)

Letter Oncology

Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity

Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction

Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen

Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li

Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Peptide absent sequences emerging in human cancers

Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares

Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.

EUROPEAN JOURNAL OF CANCER (2024)